Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Poorvu, M.D.

Concepts (89)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Gonadotropin-Releasing Hormone2201811490.860 Why?
Breast Neoplasms82020188860.680 Why?
Ovariectomy120186800.610 Why?
Uterine Hemorrhage120152300.560 Why?
Ovary1201810110.530 Why?
Amenorrhea120154860.470 Why?
Organs at Risk120123160.430 Why?
Radiation Injuries2201312870.360 Why?
Radiotherapy, Intensity-Modulated220137540.350 Why?
Endometrial Neoplasms2201312540.340 Why?
Gastrointestinal Tract120127920.320 Why?
Preoperative Care1201523990.310 Why?
Neoplasm Recurrence, Local2202081000.240 Why?
Receptors, Estrogen3202020760.240 Why?
Uterine Cervical Neoplasms1201218130.230 Why?
Quality of Life2202099870.230 Why?
Receptor, erbB-23202022200.220 Why?
Hematopoietic Stem Cell Transplantation1201545670.200 Why?
Antineoplastic Combined Chemotherapy Protocols22020105540.180 Why?
BRCA2 Protein120206450.160 Why?
Goserelin120151330.150 Why?
Contraceptive Agents, Female120151170.140 Why?
Leuprolide120153140.140 Why?
BRCA1 Protein120209950.140 Why?
Tamoxifen120189670.130 Why?
Germ-Line Mutation1202015730.130 Why?
Lymphatic Irradiation120121080.130 Why?
Mastectomy1202016280.120 Why?
Lymphatic Metastasis1201930300.110 Why?
Dose-Response Relationship, Radiation1201210070.110 Why?
Guidelines as Topic1201814390.110 Why?
Radiation-Sensitizing Agents120124110.110 Why?
Neoadjuvant Therapy1202021700.110 Why?
Chemotherapy, Adjuvant1201833730.100 Why?
Duodenum120125190.100 Why?
Lymph Nodes1201933200.090 Why?
Female1120203631150.080 Why?
Decision Support Techniques1201720030.080 Why?
Neoplasm Metastasis1201852840.080 Why?
Cisplatin1201216910.080 Why?
Intestine, Small1201213170.080 Why?
Central Nervous System Neoplasms120137610.080 Why?
Age Factors32020189860.080 Why?
Multivariate Analysis12019127320.070 Why?
Humans1220206553610.070 Why?
Aorta1201221280.070 Why?
Colon1201217520.070 Why?
Young Adult32020535700.060 Why?
Retrospective Studies52020624750.060 Why?
Gene Expression Profiling1201994400.060 Why?
Analysis of Variance1201267760.060 Why?
Decision Making1201738350.060 Why?
Adult720202051600.060 Why?
Treatment Outcome32020587760.060 Why?
Medicare1201846560.060 Why?
Aged, 80 and over32018574720.060 Why?
Adolescent32019821340.060 Why?
Cohort Studies22020369330.050 Why?
Combined Modality Therapy1201290260.050 Why?
Prospective Studies22020464980.050 Why?
Prognosis12019278740.050 Why?
Pregnancy Rate120205170.040 Why?
Live Birth120203840.040 Why?
Disease-Free Survival2202070700.040 Why?
Body Image120205730.040 Why?
Congenital Abnormalities120207070.040 Why?
Aged320181559300.040 Why?
Anorexia120131310.030 Why?
Child22015679830.030 Why?
United States12018626660.030 Why?
Nausea120136430.030 Why?
Alopecia120133230.030 Why?
Vomiting120136350.030 Why?
Radiotherapy Dosage1201329240.020 Why?
Anxiety1202033520.020 Why?
Pregnancy Complications1202027840.020 Why?
Sleep Initiation and Maintenance Disorders120137520.020 Why?
Headache1201310060.020 Why?
Time Factors22020417240.020 Why?
Kaplan-Meier Estimate1201368170.010 Why?
Depression1202064280.010 Why?
Middle Aged220132095910.010 Why?
Pregnancy12020245290.010 Why?
Risk Assessment12020227610.010 Why?
Positron-Emission Tomography1201356720.010 Why?
Risk Factors12020664170.010 Why?
Infant12013328070.010 Why?
Child, Preschool12013400320.010 Why?
Male120133419900.000 Why?
Poorvu's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (89)
Co-Authors (29)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.